Dyne Therapeutics, Inc. (DYN)

Market Cap	1.44B
Revenue (ttm)	n/a
Net Income (ttm)	-294.51M
Shares Out	101.77M
EPS (ttm)	-3.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,419,079
Open	14.89
Previous Close	14.77
Day's Range	14.03 - 14.95
52-Week Range	14.03 - 47.45
Beta	1.16
Analysts	Strong Buy
Price Target	50.70 (+258.81%)
Earnings Date	Mar 4, 2025

About DYN

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2020
• Employees: 141
• Stock Exchange: NASDAQ
• Ticker Symbol: DYN
• Website: https://www.dyne-tx.com

Analyst Forecast

According to 10 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price forecast is $50.7, which is an increase of 258.81% from the latest price.

Price Target

$50.7

(258.81% upside)

Analyst Consensus: Strong Buy